Iowa City, IANCT07581704Now EnrollingIRB Ready

Multiple Myeloma Clinical Trial in Iowa City, IA

Access cutting-edge multiple myeloma treatment through this phase 1 clinical trial at a research site in Iowa City. Study-provided care at no cost to qualified participants.

Sponsored by Christopher Strouse

Quick Self-Assessment

See if you qualify for this Iowa City location

Preparing your pre-screening questions…

Expert Care in Iowa City

Access multiple myeloma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related multiple myeloma treatment provided free

Apply for This Iowa City Location

Check if you qualify for this multiple myeloma clinical trial in Iowa City, IA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Iowa City

    Convenient for IA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Iowa City site if eligible
  4. 4Begin participation

About This Multiple Myeloma Study in Iowa City

This is a single center, single arm Phase Ib study with expansion cohort designed to establish the safety and physiologic effects of sirolimus pre-conditioning followed by T-cell engaging bispecific antibody therapy.

Sponsor: Christopher Strouse

Who Can Participate

Inclusion Criteria

To be eligible to participate in this study, an individual must meet all of the following criteria:
Willingness and ability to provide signed and dated informed consent form.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Aged 18 years of older.
Diagnosis with multiple myeloma, per IMWG Consensus Criteria.20
Planned for treatment with teclistamab, or talquetamab per standard of care, label indications.15
Prior exposure to any of the following types of T-cell engaging therapies.
Anti-BCMA x CD3 bispecific antibody (for example: teclistamab, elranatamab)
Anti-GPRC5d x CD3 bispecific antibody (for example: talquetamab)
Anti-GPRC5d x CD3 x CD38 trispecific antibody
Anti-BCMA x CD3 x CD38 trispecific antibody
Anti-BCMA x CD3 x GPRC5d trispecific antibody
Anti-BCMA chimeric antigen T-cell (for example: idecabtagene vicleucel, ciltacabtagene autoleucel)
Anti-FcRL5 x CD3 bispecific antibody
Required clinical laboratory values during screening phase Hematologic Parameters Hemoglobin ≥7.0 g/dL; Platelets ≥25 x 109/L; Absolute Lymphocyte Count ≥0.2 x 109/L Chemistries AST/ALT \< 5 x the ULN; Total Bilirubin \< 3 x the ULN
Ability to take oral medication and be willing to adhere to the sirolimus pre-conditioning regimen.
ECOG performance status of 0, 1, or 2 (KPS of \>50).
For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner per section5.3.
Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration.

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:
Participants whose multiple myeloma is progressing at a rapid pace requiring immediate anti-myeloma therapy per assessment by the principal investigator or enrolling investigator are excluded.
Excluded concomitant medication exposures:
Exposure to corticosteroids within 1 week of treatment start
Exposure to calcineurin inhibitor or mTOR inhibitors (tacrolimus, everolimus, temsirolimus, sirolimus)
Immunomodulatory monoclonal antibodies targeting tumor necrosis factor alpha (e.g. infliximab), interleukin 6 (e.g. siltuximab),
Janus kinase inhibitors (e.g. ruxolitinib)
Any other investigational drug within 28 days
History of allogeneic hematopoietic cell transplantation.
Excluded concurrent medical conditions:
Active uncontrolled infection within 7 days prior to treatment start
Uncontrolled thrombotic event within 3 months of treatment start
Acute myocardial infarction or acute coronary syndrome within 6 months of start of treatment
Uncontrolled inflammatory bowel disease
Active hepatitis B virus, hepatitis C virus, or Human Immunodeficiency Virus infection
Uncontrolled rheumatologic conditions
Use of ACE-inhibitor therapy within 1 week of treatment start
Patients found to be taking ace-inhibitor therapy during screening can be included if the ace-inhibitor is substituted for an angiotensin receptor blocking agent. (https://drug-interactions.medicine.iu.edu/main-table)
CYP3A4/p-gp inhibitors and inducers for 7 days prior to sirolimus doses and 7 days after sirolimus doses(see appendix A for list)
Any other current active malignancy or history of metastatic malignancy that has the potential to interfere with the safety or efficacy assessment of the investigational intervention
Pregnancy or lactation.
Known allergic reactions to study agent (sirolimus).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Iowa City?

Yes, this clinical trial (NCT07581704) has an active research site in Iowa City, IA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Myeloma Treatment Options in Iowa City, IA

If you're searching for multiple myeloma treatment options in Iowa City, IA, this clinical trial (NCT07581704) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Iowa City research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple myeloma clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Iowa City, IA

See all multiple myeloma clinical trials recruiting in Iowa City — not just this study.

Browse Multiple Myeloma Trials in Iowa City →

Browse More Trials by Condition

Multiple Myeloma TrialsAll Conditions →

Ready to Join in Iowa City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Iowa City, IA